A Study of Orforglipron (LY3502970) to Compare a Single Capsule and Multiple Capsules in Healthy Participants

Inclusion Criteria:

• Have a stable body weight, that is, less than a 5% body weight change, for 1 monthprior to randomization and body mass index (BMI) within the range 23.0 to 35.0kilogram per square meter (kg/m²), inclusive

• Have safety laboratory test results within normal reference range for the populationor investigative site, or results with acceptable deviations that are judged to benot clinically significant by the investigator

• Have venous access sufficient to allow for blood sampling

• Are reliable and willing to make themselves available for the duration of the studyand are willing to follow study procedures

Exclusion Criteria:

• Have a hemoglobin A1c (HbA1c) test level greater than or equal to 6.5%

• Have an estimated glomerular filtration rate less than 30 milliliter per minute per 1.73 square meter (mL/min/1.73m²)

• Have a history of significant active or unstable major depressive disorder or othersevere psychiatric disorder, for example, schizophrenia, bipolar disorder, or otherserious mood or anxiety disorder within the 2 years prior to screening

• Actively suicidal and therefore deemed to be at significant risk for suicide

• Have a known clinically significant gastric emptying abnormality

• Have history or presence of acute or chronic pancreatitis or an elevation in serumlipase or amylase levels greater than 3 times the upper limit of normal (ULN)

• Have an abnormal blood pressure (BP), pulse rate, or both

• Have difficulty swallowing capsules